Combining bioreductive drugs and radiation for the treatment of solid tumors

被引：22

作者：

Stratford, IJ ^{[1
]}

Williams, KJ ^{[1
]}

Cowen, RL ^{[1
]}

Jaffar, M ^{[1
]}

机构：

[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England

来源：

SEMINARS IN RADIATION ONCOLOGY | 2003年 / 13卷 / 01期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1053/srao.2003.50008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods now exist for the identification of human tumors that contain significant numbers of hypoxic cells and are thereby suitable for treatment with bioreductive drugs to eliminate this refractory cell population. However, to fully exploit the potential of bioreductive drugs, they will need to be used in combination with other modalities likely to target the proliferating aerobic cells in the tumor. Radiation is the treatment that is most effective in killing aerobic cells; therefore, the present report reviews the available preclinical data on combined radiation/bioreductive drug treatments. Copyright 2003, Elsevier Science (USA). All rights reserved.

引用

页码：42 / 52

页数：11

共 84 条

[31] Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice [J].

Lee, AE ;

Wilson, WR .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2000, 163 (01) :50-59

[32]

Loncaster JA, 2001, CANCER RES, V61, P6394

[33]

MARSHALL RS, 1986, CANCER RES, V46, P2709

[34] AQ4N - AN ALKYLAMINOANTHRAQUINONE N-OXIDE SHOWING BIOREDUCTIVE POTENTIAL AND POSITIVE INTERACTION WITH RADIATION IN-VIVO [J].

MCKEOWN, SR ;

HEJMADI, MV ;

MCINTYRE, IA ;

MCALEER, JJA ;

PATTERSON, LH .

BRITISH JOURNAL OF CANCER, 1995, 72 (01) :76-81

[35]

McKeown SR, 1996, BRIT J CANCER, V74, pS39

[36] Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours [J].

McNally, VA ;

Patterson, AV ;

Williams, KJ ;

Cowen, RL ;

Stratford, IJ ;

Jaffar, M .

CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (15) :1319-1333

[37]

MOHINDRA JK, 1976, CANCER RES, V36, P930

[38]

MULCAHY RT, 1984, CANCER RES, V44, P4409

[39] INDUCTION OF DNA CROSS-LINKS INVITRO UPON REDUCTION OF THE NITROIMIDAZOLE-AZIRIDINES RSU-1069 AND RSU-1131 [J].

ONEILL, P ;

MCNEIL, SS ;

JENKINS, TC .

BIOCHEMICAL PHARMACOLOGY, 1987, 36 (11) :1787-1792

[40] A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma, results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85 [J].

Overgaard, J ;

Hansen, HS ;

Overgaard, M ;

Bastholt, L ;

Berthelsen, A ;

Specht, L ;

Lindelov, B ;

Jorgensen, K .

RADIOTHERAPY AND ONCOLOGY, 1998, 46 (02) :135-146

← 1 2 3 4 5 6 7 8 9 →